You are here

  • Home
  • Archive
  • Volume 5, Issue 1
  • Improved survival and tumor control with Interleukin-2 is associated with the development of immune-related adverse events: data from the PROCLAIMSM registry

Article metrics

Article menu

Download PDFPDF

Research Article
Improved survival and tumor control with Interleukin-2 is associated with the development of immune-related adverse events: data from the PROCLAIMSM registry

 

Online download statistics by month:

Online download statistics by month: December 2019 to March 2026

AbstractFullPdf
Dec 2019110
Jan 202011112
Feb 202026263
Mar 202020201
Apr 202016166
May 2020272719
Jun 202013133
Jul 202015153
Aug 2020151512
Sep 202022221
Oct 202037372
Nov 202018172
Dec 2020664
Jan 202111112
Feb 202117178
Mar 2021262610
Apr 2021222211
May 202119195
Jun 202115153
Jul 202122225
Aug 202127269
Sep 202136368
Oct 2021363611
Nov 202119193
Dec 202138389
Jan 202218207
Feb 202217174
Mar 202234354
Apr 202231346
May 2022353611
Jun 202227273
Jul 202225265
Aug 202220204
Sep 202247472
Oct 202228284
Nov 2022155912
Dec 202219197
Jan 202330307
Feb 202345457
Mar 202319193
Apr 202324255
May 202315155
Jun 2023660
Jul 202319205
Aug 202325254
Sep 202316163
Oct 202326265
Nov 202349496
Dec 202315415412
Jan 202428297
Feb 202416161
Mar 2024474712
Apr 202427297
May 2024202112
Jun 2024353615
Jul 202446478
Aug 202420278
Sep 2024303016
Oct 202422229
Nov 202433346
Dec 2024636314
Jan 2025212410
Feb 2025232412
Mar 2025363719
Apr 2025545420
May 2025333312
Jun 2025373814
Jul 2025110
Mar 2026110
Total18521924475